Compare · MRK vs NVCT
MRK vs NVCT
Side-by-side comparison of Merck & Company Inc. (MRK) and Nuvectis Pharma Inc. (NVCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and NVCT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $317.77B, about 440.6x NVCT ($721.2M).
- Over the past year, MRK is up 62.8% and NVCT is up 251.9% - NVCT leads by 189.1 points.
- MRK has been more active in the news (25 items in the past 4 weeks vs 7 for NVCT).
- MRK has more recent analyst coverage (25 ratings vs 4 for NVCT).
- Company
- Merck & Company Inc.
- Nuvectis Pharma Inc.
- Price
- $128.37+2.34%
- $27.18-2.53%
- Market cap
- $317.77B
- $721.2M
- 1M return
- +6.74%
- +167.31%
- 1Y return
- +62.78%
- +251.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 25
- 7
- Recent ratings
- 25
- 4
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Nuvectis Pharma Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest MRK
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.
- SEC Form 11-K filed by Merck & Company Inc.
- SEC Form 11-K filed by Merck & Company Inc.
- The Quest to Repair What Multiple Sclerosis Takes Away
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
- Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
- Merck Animal Health to Acquire TARGAN
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Latest NVCT
- Nuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
- Director Hoberman Kenneth was granted 35,000 shares, increasing direct ownership by 26% to 168,140 units (SEC Form 4)
- Director Oliviero James F Iii was granted 35,000 shares, increasing direct ownership by 40% to 122,828 units (SEC Form 4)
- Director Sanchez Juan was granted 35,000 shares, increasing direct ownership by 45% to 113,380 units (SEC Form 4)
- Director Kaplan Matthew L. was granted 35,000 shares, increasing direct ownership by 28% to 159,760 units (SEC Form 4)
- Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- SEC Form 10-Q filed by Nuvectis Pharma Inc.
- Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits